The aims of the present study were to (i) determine the composition of Nosustrophine, and (ii) analyze, using a transgenic (APP/BIN1/COPS5) mouse model of AD, whether Nosustrophine acts as an epinutraceutical by modulating the epigenetic machinery that promotes AD progression. The gene discussed is APP; the disease is Alzheimer disease.